Incidence and risk factors of interstitial lung disease of patients with head and neck cancer treated with cetuximab

Nakano, Kenji; Seto, Akira; Sasaki, Tōru; Shimbashi, Wataru; Fukushima, Hirofumi; Yonekawa, Hiroyuki; Mitani, Hiroki; Takahashi, Shunji

doi:10.1002/hed.25727

Cited by 10 publications

(11 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Many factors can damage AECs, such as preexisting pulmonary diseases, including chronic obstructive pulmonary disease (COPD), asthma and pleural effusion [32], and some anticancer treatments, such as chemotherapy [42], targeted therapy [43] and radiotherapy [44]. In this study, we found that smoking history and pleural effusion were associated with CIP, while smoking history was an independent risk factor for CIP.…”

Section: Discussionmentioning

confidence: 75%

Establishment and validation of nomogram for predicting immuno checkpoint inhibitor related pneumonia

Wang

et al. 2022

BMC Pulm Med

View full text Add to dashboard Cite

Objective Cancer is one of the main causes of death worldwide. Although immunotherapy brings hope for cancer treatment, it is also accompanied by immune checkpoint inhibitor-related adverse events (irAEs). Immune checkpoint inhibitor pneumonia (CIP) is a potentially fatal adverse event, but there is still a lack of effective markers and prediction models to identify patients at increased risk of CIP. Methods A total of 369 cancer patients treated between 2017 and 2022 with immune checkpoint inhibitors at Shengjing Hospital of China Medical University and Liaoning People's Hospital were recruited for this study. Independent variables were selected by differences and binary logistic regression analysis, and a risk assessment nomogram was constructed for CIP risk. The accuracy and discriminative abilities of the nomogram were evaluated by calibration plots, receiver operating characteristic curves (ROCs) and decision curve analyses (DCAs). Results Binary logistic regression analysis showed that smoking history, acute phase proteins [interleukin (IL-6) and C-reactive protein (CRP)], CD8 + T lymphocyte count and serum alveolar protein [surface protein-A (SP-A) and Krebs Von den Lungen-6 (KL-6)] were significantly associated with CIP risk. A nomogram consisting of these variables was established and validated by different analyses. Conclusions We developed an effective risk nomogram for CIP prediction in immune-checkpoint inhibitor administrated cancer patients, which will further assist early detection of immunotherapy-related adverse events.

show abstract

Section: Discussionmentioning

confidence: 75%

Establishment and validation of nomogram for predicting immuno checkpoint inhibitor related pneumonia

Wang

et al. 2022

BMC Pulm Med

View full text Add to dashboard Cite

show abstract

“…The DILD toxicity of cetuximab might be dose-dependent, and the biweekly regimen is now approved for use, but the concerns over the development of DILD should remain. [3,5–8]…”

Section: Discussionmentioning

confidence: 99%

Case report: Interstitial lung disease of XELOEX chemotherapy with cetuximab in advanced colon cancer induced

Shao,

Hu,

Yao

et al. 2023

Medicine

View full text Add to dashboard Cite

Introduction: This paper presents a case of a Chinese patient with advanced colon cancer who developed drug-induced interstitial lung disease while undergoing treatment with cetuximab combined with XELOX. Patient concerns: A 75-year-old man with a history of colon cancer, had metastases in the liver, peritoneum, and lungs, which were initially treated with XELOX and cetuximab (0.4 g) in 2019. However, the lung metastases progressed, and the cetuximab dosage was adjusted to 0.9 g and then readjusted to 0.4 g. Diagnosis: In January 2021, computed tomography revealed developed interstitial lung disease, leading to the discontinuation of chemotherapy and cetuximab. Interventions: Receiving methylprednisolone pulse therapy. Outcomes: The patient experienced respiratory failure and passed away. The Naranjo Algorithm Assessment score indicated a probable relationship between cetuximab and the adverse event. Conclusion: This case highlights the need for regular pulmonary imaging examinations during cetuximab therapy, as drug-induced interstitial lung disease may be associated with the dose and duration of treatment.

show abstract

“…In another retrospective study of patients with head and neck tumors, the incidence of interstitial pneumonia during cetuximab treatment was 4.5% (9/201), of which 8 cases were grade 3 or higher. High salivation liquefaction sugar chain antigen-6 and smoking history may be risk factors for interstitial pneumonia in patients with head and neck tumors [16].…”

Section: Discussionmentioning

confidence: 99%

“…Reviewing the literature reports on interstitial pneumonia caused by cetuximab [11][12][13][14][15][16], there is no certain trend in the onset time of interstitial pneumonia caused by cetuximab. A Japanese study has reported that the incidence of cetuximab-related lung injury occurring in patients with metastatic colorectal cancer was 1.2% (24/2006), the incidence of grade 3 or higher was 0.7% (15/2006) and the median time of onset was 101 days (17-431 days).…”

Section: Discussionmentioning

confidence: 99%

Severe interstitial pneumonia caused by cetuximab: a case report and review of the literature

et al. 2021

View full text Add to dashboard Cite

Cetuximab is an IgG1 chimeric mAb against epidermal growth factor receptor, which can be used for chemotherapy failure or tolerance in patients with epidermal growth factor receptor expressed RAS wildtype metastatic colorectal cancer. We report on a patient who developed rapid-onset interstitial pneumonia while being treated with cetuximab plus XELOX (oxaliplatin, capecitabine) for metastatic colorectal cancer. A 75-yearold man patient was administered cetuximab plus XELOX regularly. After his cetuximab schedule was adjusted from 1 to 2 weeks, he rapidly developed interstitial pneumonia which led to acute respiratory distress syndrome. Our literature review indicated that, for patients with risk factors, a 2-week regimen of cetuximab might lead to interstitial pneumonia. Clinicians should closely monitor patients for adverse drug reactions to improve drug safety.

show abstract

Incidence and risk factors of interstitial lung disease of patients with head and neck cancer treated with cetuximab

Cited by 10 publications

References 26 publications

Establishment and validation of nomogram for predicting immuno checkpoint inhibitor related pneumonia

Establishment and validation of nomogram for predicting immuno checkpoint inhibitor related pneumonia

Case report: Interstitial lung disease of XELOEX chemotherapy with cetuximab in advanced colon cancer induced

Severe interstitial pneumonia caused by cetuximab: a case report and review of the literature

Contact Info

Product

Resources

About